880 related articles for article (PubMed ID: 33484582)
1. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
3. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
Ferreira S; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
5. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
8. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Nezamololama N; Crowley EL; Gooderham MJ; Papp K
Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
[TBL] [Abstract][Full Text] [Related]
9. Journal club: New small molecules for atopic dermatitis management.
Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E
Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
Wan H; Jia H; Xia T; Zhang D
Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.
Mendes JT; Balogh EA; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 Jun; 21(9):1027-1033. PubMed ID: 32208940
[TBL] [Abstract][Full Text] [Related]
14. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
15. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
16. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Bissonnette R; Maari C; Forman S; Bhatia N; Lee M; Fowler J; Tyring S; Pariser D; Sofen H; Dhawan S; Zook M; Zammit DJ; Usansky H; Denis L; Rao N; Song T; Pavel AB; Guttman-Yassky E
Br J Dermatol; 2019 Oct; 181(4):733-742. PubMed ID: 30919407
[TBL] [Abstract][Full Text] [Related]
17. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
18. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.
Napolitano M; Fabbrocini G; Ruggiero A; Marino V; Nocerino M; Patruno C
Drug Des Devel Ther; 2021; 15():1135-1147. PubMed ID: 33731985
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]